Kazia Therapeutics Limited

NasdaqCM KZIA

Kazia Therapeutics Limited EBT Margin for the year ending June 30, 2024: -1,171.97%

Kazia Therapeutics Limited EBT Margin is -1,171.97% for the year ending June 30, 2024, a 99.97% change year over year. EBT Ratio (Earnings Before Tax Ratio) is the fraction of earnings before taxes to total revenue, indicating the company's profitability before the impact of tax expenses.

Kazia Therapeutics Limited EBT Margin for the year ending June 30, 2023 was -3,736,265.23%, a 96.27% change year over year.
Kazia Therapeutics Limited EBT Margin for the year ending June 30, 2022 was -100,063,580.00%, a -170,579,739.29% change year over year.
Kazia Therapeutics Limited EBT Margin for the year ending June 30, 2021 was -58.66%, a 100.00% change year over year.
Kazia Therapeutics Limited EBT Margin for the year ending June 30, 2020 was -1,203,110.27%, a -78.17% change year over year.

Key data

Date	EBT Margin	Net Income Margin	EBITDA Margin	EBIT Margin

NasdaqCM: KZIA

Kazia Therapeutics Limited

CEO	Dr. John Edwin Friend II, M.D.
IPO Date	Jan. 6, 1999
Location	Australia
Headquarters	Three International Towers
Employees	9
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.

Key trends

Past 5 years